[Bisphosphonates and osteonecrosis of the jaw--an increasing challenge in palliative care].
Bone metastases are one of the most common complications of cancer. Up to 70% of patients with advanced breast cancer metastasize to the bone. The standard long-term treatment of bone metastases is bisphosphonates. This effective therapy, however, is able to cause serious side effects. Osteonecrosis of the jaw (ONJ) is a recently detected adverse outcome associated in rare cases with bisphosphonate therapy.
Beke
Dora
D
Interne Abteilung, Krankenhaus der Barmherzigen Brüder Wien, Wien, Osterreich. dora.beke@bbwien.at
Pecherstorfer
Martin
M
D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy; D001943:Breast Neoplasms / Q000628:therapy*; D044584:Carcinoma, Ductal / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D018450:Disease Progression; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted; D021621:Imaging, Three-Dimensional; D008336:Mandibular Diseases / Q000139:chemically induced* / Q000175:diagnosis; D008439:Maxillary Diseases / Q000139:chemically induced* / Q000175:diagnosis; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D010020:Osteonecrosis / Q000139:chemically induced* / Q000175:diagnosis; D014057:Tomography, X-Ray Computed
D050071:Bone Density Conservation Agents; D004164:Diphosphonates